Drug intelligence / Profile preview

GenSci128

Development stage: Phase 1
Lead developer: Changchun GeneScience Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GenSci128 is an investigational small molecule drug developed by Changchun GeneScience Pharmaceutical for the treatment of solid tumors harboring the TP53 Y220C mutation. It acts as a p53 Y220C activator, aiming to restore or enhance the function of mutant p53 protein in cancer cells. The drug is currently being evaluated in Phase 1 clinical trials for patients with locally advanced or metastatic solid tumors that carry this specific genetic alteration. GenSci128 is administered orally and represents a targeted approach to treating cancers driven by TP53 Y220C mutations[1][2][3][7].

Targets

TP53 Y220C (Tumor suppressor protein p53 Y220C mutant)

Beyond the preview

Go deeper on GenSci128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenSci128.

Explore the full profile